首页> 美国卫生研究院文献>Therapeutic Advances in Psychopharmacology >The therapeutic potential of microdosing psychedelics in depression
【2h】

The therapeutic potential of microdosing psychedelics in depression

机译:微型迷幻抑郁症的治疗潜力

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Microdosing psychedelics is the repeated use of small doses of, for example, lysergic acid diethylamide (LSD) and psilocybin, typically for a few weeks. Despite the popular and scientific attention in recent years, and claims by users that it has therapeutic value in affective disorders like depression, little scientific knowledge is available to back this. The purpose of this review was to investigate whether there are scientific grounds to state that this practice could be helpful in the treatment of affective disorders, and safe to use repeatedly. To that end, the literature (PubMed, MedLine) was searched, looking for (controlled) experimental studies with low doses of LSD and/or psilocybin, in healthy volunteers and patient samples. After a selection process and the addition of relevant articles, 14 experimental studies entered this review. Findings show that both LSD (10–20 mcg) and psilocybin (<1–3 mg) have subtle (positive) effects on cognitive processes (time perception, convergent and divergent thinking) and brain regions involved in affective processes. Besides the pleasant experience, increased anxiety and a cycling pattern of depressive and euphoric mood were also found. With regard to safety, it was demonstrated that low doses are well tolerated (in healthy volunteers) and have no-to-minimal effects on physiological measures. While it is yet unclear whether psychedelic microdosing is of therapeutic value for depression, the aforementioned effects on selective processes suggest that low doses of psychedelics could play a role in depression by inducing some kind of cognitive flexibility, which might lead to decreased rumination. While previous studies were conducted mostly in small samples of healthy volunteers, future placebo-controlled clinical trials in depressed patients are required to understand the therapeutic value of microdosing psychedelics, how this differs from therapy using full psychedelic doses, and whether different psychedelics have different effect patterns. The proposed research will give new insights into the potential of future alternative psychiatric treatment forms that are fiercely needed.
机译:微型迷幻性是重复使用小剂量的小剂量,例如赖乙酸二乙胺(LSD)和Psilocybin,通常几周。尽管近年来,尽管近年来的受欢迎和科学的关注,并由用户索赔具有抑郁症的情感障碍中具有治疗价值,因此可以向此提供小科学知识。本综述的目的是调查是否有科学的理由是说明这种做法可能有助于治疗情感障碍,并安全地反复使用。为此,搜查了文献(PubMed,Medline),寻找(受控)实验研究,低剂量的LSD和/或Psilocybin,在健康的志愿者和患者样品中。在选择过程和添加相关文章之后,14项实验研究进入了这一综述。调查结果表明,LSD(10-20mg)和psilocybin(<1-3mg)对认知过程(时间感知,收敛和发散思维)和脑区涉及情感过程的脑区。除了令人愉快的经历,还发现了令人愉快的经验,增加焦虑和抑郁和欣快情绪的循环模式。关于安全性,证明低剂量耐受良好(在健康的志愿者中),对生理措施具有无缺点。虽然目前尚不清楚迷幻微型是否具有抑郁症的治疗价值,但对选择性过程的上述作用表明,低剂量的迷幻学通过诱导某种认知灵活性,可能会发挥抑郁症的作用,这可能导致谣言降低。虽然以前的研究主要是在健康志愿者的小样本中进行的,但是需要在抑郁症患者中进行未来的安慰剂临床试验,以了解微型迷幻学的治疗价值,如何使用全敏感剂量与治疗不同,以及不同的荧光性是否有不同的效果模式。拟议的研究将为未来替代精神治疗形式的潜力提供新的见解,这是强烈需要的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号